Global Pharma 4.0 Market by End User (Ambulatory Surgical Centers, Hospitals), by Design (Data Integrity, Digital Maturity, Capabilities), by Technology (Big Data Analytics, Cyber-physical Systems, Cloud Computing) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “Pharma 4.0 Market research report which is segmented by End User (Ambulatory Surgical Centers, Hospitals), by Design (Data Integrity, Digital Maturity, Capabilities), by Technology (Big Data Analytics, Cyber-physical Systems, Cloud Computing), By Players/Companies Vertex, Koninklijke Philips N.V., Lonza Group AG, GE Healthcare, Medtronic Plc., Glatt GmbH, Boston Scientific, GlaxoSmithKline plc., Pfizer Inc., Abbott Laboratories, Johnson & Johnson”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Pharma 4.0 Market Research Report |
| By End User | Ambulatory Surgical Centers, Hospitals |
| By Design | Data Integrity, Digital Maturity, Capabilities |
| By Technology | Big Data Analytics, Cyber-physical Systems, Cloud Computing |
| By Companies | Vertex, Koninklijke Philips N.V., Lonza Group AG, GE Healthcare, Medtronic Plc., Glatt GmbH, Boston Scientific, GlaxoSmithKline plc., Pfizer Inc., Abbott Laboratories, Johnson & Johnson |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 241 |
| Number of Tables & Figures | 169 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Pharma 4.0 Market Report Segments:
The market is segmented by End User (Ambulatory Surgical Centers, Hospitals), by Design (Data Integrity, Digital Maturity, Capabilities), by Technology (Big Data Analytics, Cyber-physical Systems, Cloud Computing).
Pharma 4.0 Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Pharma 4.0 Market
Overview of the regional outlook of the Pharma 4.0 Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Pharma 4.0 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Pharma 4.0 Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Ambulatory Surgical Centers
2. Hospitals
7. By Design:1. Data Integrity
2. Digital Maturity
3. Capabilities
8. By Technology:1. Big Data Analytics
2. Cyber-physical Systems
3. Cloud Computing
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pharma 4.0 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Pharma 4.0 Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pharma 4.0 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pharma 4.0 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pharma 4.0 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pharma 4.0 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pharma 4.0 Market Size & Forecast, 2018-2028
4.5.1 Pharma 4.0 Market Size and Y-o-Y Growth
4.5.2 Pharma 4.0 Market Absolute $ Opportunity
Chapter 5 Global Pharma 4.0 Market Analysis and Forecast by End User
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by End User
5.1.2 Basis Point Share (BPS) Analysis by End User
5.1.3 Absolute $ Opportunity Assessment by End User
5.2 Pharma 4.0 Market Size Forecast by End User
5.2.1 Ambulatory Surgical Centers
5.2.2 Hospitals
5.3 Market Attractiveness Analysis by End User
Chapter 6 Global Pharma 4.0 Market Analysis and Forecast by Design
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Design
6.1.2 Basis Point Share (BPS) Analysis by Design
6.1.3 Absolute $ Opportunity Assessment by Design
6.2 Pharma 4.0 Market Size Forecast by Design
6.2.1 Data Integrity
6.2.2 Digital Maturity
6.2.3 Capabilities
6.3 Market Attractiveness Analysis by Design
Chapter 7 Global Pharma 4.0 Market Analysis and Forecast by Technology
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Technology
7.1.2 Basis Point Share (BPS) Analysis by Technology
7.1.3 Absolute $ Opportunity Assessment by Technology
7.2 Pharma 4.0 Market Size Forecast by Technology
7.2.1 Big Data Analytics
7.2.2 Cyber-physical Systems
7.2.3 Cloud Computing
7.3 Market Attractiveness Analysis by Technology
Chapter 8 Global Pharma 4.0 Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Pharma 4.0 Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Pharma 4.0 Analysis and Forecast
10.1 Introduction
10.2 North America Pharma 4.0 Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Pharma 4.0 Market Size Forecast by End User
10.6.1 Ambulatory Surgical Centers
10.6.2 Hospitals
10.7 Basis Point Share (BPS) Analysis by End User
10.8 Absolute $ Opportunity Assessment by End User
10.9 Market Attractiveness Analysis by End User
10.10 North America Pharma 4.0 Market Size Forecast by Design
10.10.1 Data Integrity
10.10.2 Digital Maturity
10.10.3 Capabilities
10.11 Basis Point Share (BPS) Analysis by Design
10.12 Absolute $ Opportunity Assessment by Design
10.13 Market Attractiveness Analysis by Design
10.14 North America Pharma 4.0 Market Size Forecast by Technology
10.14.1 Big Data Analytics
10.14.2 Cyber-physical Systems
10.14.3 Cloud Computing
10.15 Basis Point Share (BPS) Analysis by Technology
10.16 Absolute $ Opportunity Assessment by Technology
10.17 Market Attractiveness Analysis by Technology
Chapter 11 Europe Pharma 4.0 Analysis and Forecast
11.1 Introduction
11.2 Europe Pharma 4.0 Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Pharma 4.0 Market Size Forecast by End User
11.6.1 Ambulatory Surgical Centers
11.6.2 Hospitals
11.7 Basis Point Share (BPS) Analysis by End User
11.8 Absolute $ Opportunity Assessment by End User
11.9 Market Attractiveness Analysis by End User
11.10 Europe Pharma 4.0 Market Size Forecast by Design
11.10.1 Data Integrity
11.10.2 Digital Maturity
11.10.3 Capabilities
11.11 Basis Point Share (BPS) Analysis by Design
11.12 Absolute $ Opportunity Assessment by Design
11.13 Market Attractiveness Analysis by Design
11.14 Europe Pharma 4.0 Market Size Forecast by Technology
11.14.1 Big Data Analytics
11.14.2 Cyber-physical Systems
11.14.3 Cloud Computing
11.15 Basis Point Share (BPS) Analysis by Technology
11.16 Absolute $ Opportunity Assessment by Technology
11.17 Market Attractiveness Analysis by Technology
Chapter 12 Asia Pacific Pharma 4.0 Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Pharma 4.0 Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Pharma 4.0 Market Size Forecast by End User
12.6.1 Ambulatory Surgical Centers
12.6.2 Hospitals
12.7 Basis Point Share (BPS) Analysis by End User
12.8 Absolute $ Opportunity Assessment by End User
12.9 Market Attractiveness Analysis by End User
12.10 Asia Pacific Pharma 4.0 Market Size Forecast by Design
12.10.1 Data Integrity
12.10.2 Digital Maturity
12.10.3 Capabilities
12.11 Basis Point Share (BPS) Analysis by Design
12.12 Absolute $ Opportunity Assessment by Design
12.13 Market Attractiveness Analysis by Design
12.14 Asia Pacific Pharma 4.0 Market Size Forecast by Technology
12.14.1 Big Data Analytics
12.14.2 Cyber-physical Systems
12.14.3 Cloud Computing
12.15 Basis Point Share (BPS) Analysis by Technology
12.16 Absolute $ Opportunity Assessment by Technology
12.17 Market Attractiveness Analysis by Technology
Chapter 13 Latin America Pharma 4.0 Analysis and Forecast
13.1 Introduction
13.2 Latin America Pharma 4.0 Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Pharma 4.0 Market Size Forecast by End User
13.6.1 Ambulatory Surgical Centers
13.6.2 Hospitals
13.7 Basis Point Share (BPS) Analysis by End User
13.8 Absolute $ Opportunity Assessment by End User
13.9 Market Attractiveness Analysis by End User
13.10 Latin America Pharma 4.0 Market Size Forecast by Design
13.10.1 Data Integrity
13.10.2 Digital Maturity
13.10.3 Capabilities
13.11 Basis Point Share (BPS) Analysis by Design
13.12 Absolute $ Opportunity Assessment by Design
13.13 Market Attractiveness Analysis by Design
13.14 Latin America Pharma 4.0 Market Size Forecast by Technology
13.14.1 Big Data Analytics
13.14.2 Cyber-physical Systems
13.14.3 Cloud Computing
13.15 Basis Point Share (BPS) Analysis by Technology
13.16 Absolute $ Opportunity Assessment by Technology
13.17 Market Attractiveness Analysis by Technology
Chapter 14 Middle East & Africa (MEA) Pharma 4.0 Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Pharma 4.0 Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Pharma 4.0 Market Size Forecast by End User
14.6.1 Ambulatory Surgical Centers
14.6.2 Hospitals
14.7 Basis Point Share (BPS) Analysis by End User
14.8 Absolute $ Opportunity Assessment by End User
14.9 Market Attractiveness Analysis by End User
14.10 Middle East & Africa (MEA) Pharma 4.0 Market Size Forecast by Design
14.10.1 Data Integrity
14.10.2 Digital Maturity
14.10.3 Capabilities
14.11 Basis Point Share (BPS) Analysis by Design
14.12 Absolute $ Opportunity Assessment by Design
14.13 Market Attractiveness Analysis by Design
14.14 Middle East & Africa (MEA) Pharma 4.0 Market Size Forecast by Technology
14.14.1 Big Data Analytics
14.14.2 Cyber-physical Systems
14.14.3 Cloud Computing
14.15 Basis Point Share (BPS) Analysis by Technology
14.16 Absolute $ Opportunity Assessment by Technology
14.17 Market Attractiveness Analysis by Technology
Chapter 15 Competition Landscape
15.1 Pharma 4.0 Market: Competitive Dashboard
15.2 Global Pharma 4.0 Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Vertex
15.3.2 Koninklijke Philips N.V.
15.3.3 Lonza Group AG
15.3.4 GE Healthcare
15.3.5 Medtronic Plc.
15.3.6 Glatt GmbH
15.3.7 Boston Scientific
15.3.8 GlaxoSmithKline plc.
15.3.9 Pfizer Inc.
15.3.10 Abbott Laboratories
15.3.11 Johnson & Johnson
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pharma 4.0 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pharma 4.0 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pharma 4.0 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pharma 4.0 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pharma 4.0 Market Size & Forecast, 2018-2028
4.5.1 Pharma 4.0 Market Size and Y-o-Y Growth
4.5.2 Pharma 4.0 Market Absolute $ Opportunity
Chapter 5 Global Pharma 4.0 Market Analysis and Forecast by End User
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by End User
5.1.2 Basis Point Share (BPS) Analysis by End User
5.1.3 Absolute $ Opportunity Assessment by End User
5.2 Pharma 4.0 Market Size Forecast by End User
5.2.1 Ambulatory Surgical Centers
5.2.2 Hospitals
5.3 Market Attractiveness Analysis by End User
Chapter 6 Global Pharma 4.0 Market Analysis and Forecast by Design
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Design
6.1.2 Basis Point Share (BPS) Analysis by Design
6.1.3 Absolute $ Opportunity Assessment by Design
6.2 Pharma 4.0 Market Size Forecast by Design
6.2.1 Data Integrity
6.2.2 Digital Maturity
6.2.3 Capabilities
6.3 Market Attractiveness Analysis by Design
Chapter 7 Global Pharma 4.0 Market Analysis and Forecast by Technology
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Technology
7.1.2 Basis Point Share (BPS) Analysis by Technology
7.1.3 Absolute $ Opportunity Assessment by Technology
7.2 Pharma 4.0 Market Size Forecast by Technology
7.2.1 Big Data Analytics
7.2.2 Cyber-physical Systems
7.2.3 Cloud Computing
7.3 Market Attractiveness Analysis by Technology
Chapter 8 Global Pharma 4.0 Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Pharma 4.0 Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Pharma 4.0 Analysis and Forecast
10.1 Introduction
10.2 North America Pharma 4.0 Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Pharma 4.0 Market Size Forecast by End User
10.6.1 Ambulatory Surgical Centers
10.6.2 Hospitals
10.7 Basis Point Share (BPS) Analysis by End User
10.8 Absolute $ Opportunity Assessment by End User
10.9 Market Attractiveness Analysis by End User
10.10 North America Pharma 4.0 Market Size Forecast by Design
10.10.1 Data Integrity
10.10.2 Digital Maturity
10.10.3 Capabilities
10.11 Basis Point Share (BPS) Analysis by Design
10.12 Absolute $ Opportunity Assessment by Design
10.13 Market Attractiveness Analysis by Design
10.14 North America Pharma 4.0 Market Size Forecast by Technology
10.14.1 Big Data Analytics
10.14.2 Cyber-physical Systems
10.14.3 Cloud Computing
10.15 Basis Point Share (BPS) Analysis by Technology
10.16 Absolute $ Opportunity Assessment by Technology
10.17 Market Attractiveness Analysis by Technology
Chapter 11 Europe Pharma 4.0 Analysis and Forecast
11.1 Introduction
11.2 Europe Pharma 4.0 Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Pharma 4.0 Market Size Forecast by End User
11.6.1 Ambulatory Surgical Centers
11.6.2 Hospitals
11.7 Basis Point Share (BPS) Analysis by End User
11.8 Absolute $ Opportunity Assessment by End User
11.9 Market Attractiveness Analysis by End User
11.10 Europe Pharma 4.0 Market Size Forecast by Design
11.10.1 Data Integrity
11.10.2 Digital Maturity
11.10.3 Capabilities
11.11 Basis Point Share (BPS) Analysis by Design
11.12 Absolute $ Opportunity Assessment by Design
11.13 Market Attractiveness Analysis by Design
11.14 Europe Pharma 4.0 Market Size Forecast by Technology
11.14.1 Big Data Analytics
11.14.2 Cyber-physical Systems
11.14.3 Cloud Computing
11.15 Basis Point Share (BPS) Analysis by Technology
11.16 Absolute $ Opportunity Assessment by Technology
11.17 Market Attractiveness Analysis by Technology
Chapter 12 Asia Pacific Pharma 4.0 Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Pharma 4.0 Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Pharma 4.0 Market Size Forecast by End User
12.6.1 Ambulatory Surgical Centers
12.6.2 Hospitals
12.7 Basis Point Share (BPS) Analysis by End User
12.8 Absolute $ Opportunity Assessment by End User
12.9 Market Attractiveness Analysis by End User
12.10 Asia Pacific Pharma 4.0 Market Size Forecast by Design
12.10.1 Data Integrity
12.10.2 Digital Maturity
12.10.3 Capabilities
12.11 Basis Point Share (BPS) Analysis by Design
12.12 Absolute $ Opportunity Assessment by Design
12.13 Market Attractiveness Analysis by Design
12.14 Asia Pacific Pharma 4.0 Market Size Forecast by Technology
12.14.1 Big Data Analytics
12.14.2 Cyber-physical Systems
12.14.3 Cloud Computing
12.15 Basis Point Share (BPS) Analysis by Technology
12.16 Absolute $ Opportunity Assessment by Technology
12.17 Market Attractiveness Analysis by Technology
Chapter 13 Latin America Pharma 4.0 Analysis and Forecast
13.1 Introduction
13.2 Latin America Pharma 4.0 Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Pharma 4.0 Market Size Forecast by End User
13.6.1 Ambulatory Surgical Centers
13.6.2 Hospitals
13.7 Basis Point Share (BPS) Analysis by End User
13.8 Absolute $ Opportunity Assessment by End User
13.9 Market Attractiveness Analysis by End User
13.10 Latin America Pharma 4.0 Market Size Forecast by Design
13.10.1 Data Integrity
13.10.2 Digital Maturity
13.10.3 Capabilities
13.11 Basis Point Share (BPS) Analysis by Design
13.12 Absolute $ Opportunity Assessment by Design
13.13 Market Attractiveness Analysis by Design
13.14 Latin America Pharma 4.0 Market Size Forecast by Technology
13.14.1 Big Data Analytics
13.14.2 Cyber-physical Systems
13.14.3 Cloud Computing
13.15 Basis Point Share (BPS) Analysis by Technology
13.16 Absolute $ Opportunity Assessment by Technology
13.17 Market Attractiveness Analysis by Technology
Chapter 14 Middle East & Africa (MEA) Pharma 4.0 Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Pharma 4.0 Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Pharma 4.0 Market Size Forecast by End User
14.6.1 Ambulatory Surgical Centers
14.6.2 Hospitals
14.7 Basis Point Share (BPS) Analysis by End User
14.8 Absolute $ Opportunity Assessment by End User
14.9 Market Attractiveness Analysis by End User
14.10 Middle East & Africa (MEA) Pharma 4.0 Market Size Forecast by Design
14.10.1 Data Integrity
14.10.2 Digital Maturity
14.10.3 Capabilities
14.11 Basis Point Share (BPS) Analysis by Design
14.12 Absolute $ Opportunity Assessment by Design
14.13 Market Attractiveness Analysis by Design
14.14 Middle East & Africa (MEA) Pharma 4.0 Market Size Forecast by Technology
14.14.1 Big Data Analytics
14.14.2 Cyber-physical Systems
14.14.3 Cloud Computing
14.15 Basis Point Share (BPS) Analysis by Technology
14.16 Absolute $ Opportunity Assessment by Technology
14.17 Market Attractiveness Analysis by Technology
Chapter 15 Competition Landscape
15.1 Pharma 4.0 Market: Competitive Dashboard
15.2 Global Pharma 4.0 Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Vertex
15.3.2 Koninklijke Philips N.V.
15.3.3 Lonza Group AG
15.3.4 GE Healthcare
15.3.5 Medtronic Plc.
15.3.6 Glatt GmbH
15.3.7 Boston Scientific
15.3.8 GlaxoSmithKline plc.
15.3.9 Pfizer Inc.
15.3.10 Abbott Laboratories
15.3.11 Johnson & Johnson
Segments Covered in the Report
The global Pharma 4.0 market has been segmented based on
By End User
The global Pharma 4.0 market has been segmented based on
By End User
- Ambulatory Surgical Centers
- Hospitals
- Data Integrity
- Digital Maturity
- Capabilities
- Big Data Analytics
- Cyber-physical Systems
- Cloud Computing
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Vertex
- Koninklijke Philips N.V.
- Lonza Group AG
- GE Healthcare
- Medtronic Plc.
- Glatt GmbH
- Boston Scientific
- GlaxoSmithKline plc.
- Pfizer Inc.
- Abbott Laboratories
- Johnson & Johnson
Our Clients
Related Reports
Some other reports from this category!
